Operating Segments |
Note 4:- Operating Segments
The company has two operating segments,
as follows:
|
Proprietary Products |
Manufacturing, sales and distribution of plasma-derived protein therapeutics. |
|
Distribution |
Distribute imported drug products in Israel, which are manufactured by third parties. |
| b. | Reporting on operating segments: |
| |
Six months period ended June 30, 2025 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Unaudited | |
| |
| | |
| | |
| |
Revenues | |
$ | 78,453 | | |
$ | 10,319 | | |
$ | 88,772 | |
Gross profit | |
$ | 37,873 | | |
$ | 1,805 | | |
$ | 39,678 | |
Unallocated corporate expenses | |
| | | |
| | | |
| (24,812 | ) |
Finance expenses, net | |
| | | |
| | | |
| (2,500 | ) |
Income before taxes on income | |
| | | |
| | | |
$ | 12,366 | |
| |
Six months period ended June 30, 2024 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Unaudited | |
| |
| | |
| | |
| |
Revenues | |
$ | 72,904 | | |
$ | 7,304 | | |
$ | 80,208 | |
Gross profit | |
$ | 34,566 | | |
$ | 1,136 | | |
$ | 35,702 | |
Unallocated corporate expenses | |
| | | |
| | | |
| (26,023 | ) |
Finance expenses, net | |
| | | |
| | | |
| (2,751 | ) |
Income before taxes on income | |
| | | |
| | | |
$ | 6,928 | |
| |
Three months period ended June 30, 2025 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Unaudited | |
| |
| | |
| | |
| |
Revenues | |
$ | 38,436 | | |
$ | 6,318 | | |
$ | 44,754 | |
Gross profit | |
$ | 17,594 | | |
$ | 1,335 | | |
$ | 18,929 | |
Unallocated corporate expenses | |
| | | |
| | | |
| (11,858 | ) |
Finance expenses, net | |
| | | |
| | | |
| (1,318 | ) |
Income before taxes on income | |
| | | |
| | | |
$ | 5,753 | |
| |
Three months period ended June 30, 2024 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Unaudited | |
| |
| | |
| | |
| |
Revenues | |
$ | 39,146 | | |
$ | 3,326 | | |
$ | 42,472 | |
Gross profit | |
$ | 18,428 | | |
$ | 523 | | |
$ | 18,951 | |
Unallocated corporate expenses | |
| | | |
| | | |
| (13,311 | ) |
Finance expenses, net | |
| | | |
| | | |
| (1,151 | ) |
Income before taxes on income | |
| | | |
| | | |
$ | 4,489 | |
| |
Year Ended December 31, 2024 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Audited | |
Revenues | |
$ | 141,447 | | |
$ | 19,506 | | |
$ | 160,953 | |
Gross profit | |
$ | 67,739 | | |
$ | 2,228 | | |
$ | 69,967 | |
Unallocated corporate expenses | |
| | | |
| | | |
| (49,916 | ) |
Finance expenses, net | |
| | | |
| | | |
| (6,717 | ) |
Income before taxes on income | |
| | | |
| | | |
$ | 13,334 | |
| c. | Reporting on operating segments by geographic region: |
| |
Six months period ended June 30, 2025 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Unaudited | |
Geographical markets | |
| | |
| | |
| |
U.S.A | |
$ | 55,494 | | |
$ | - | | |
$ | 55,493 | |
Israel | |
| 3,036 | | |
| 10,319 | | |
| 13,355 | |
Latin America | |
| 9,880 | | |
| | | |
| 9,880 | |
Canada | |
| 5,595 | | |
| | | |
| 5,595 | |
Europe | |
| 2,453 | | |
| - | | |
| 2,453 | |
Asia | |
| 1,972 | | |
| - | | |
| 1,972 | |
Others | |
| 23 | | |
| | | |
| 23 | |
| |
$ | 78,453 | | |
$ | 10,319 | | |
$ | 88,772 | |
| |
Six months period ended June 30, 2024 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Unaudited | |
Geographical markets | |
| | |
| | |
| |
U.S.A | |
$ | 55,169 | | |
$ | - | | |
$ | 55,169 | |
Israel | |
| 3,557 | | |
| 7,304 | | |
| 10,861 | |
Canada | |
| 5,765 | | |
| | | |
| 5,765 | |
Europe | |
| 1,678 | | |
| - | | |
| 1,678 | |
Latin America | |
| 5,235 | | |
| - | | |
| 5,235 | |
Asia | |
| 1,500 | | |
| - | | |
| 1,500 | |
Others | |
| - | | |
| - | | |
| - | |
| |
$ | 72,904 | | |
$ | 7,304 | | |
$ | 80,208 | |
| |
Three months period ended June 30, 2025 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Unaudited | |
Geographical markets | |
| | |
| | |
| |
U.S.A | |
$ | 25,336 | | |
$ | - | | |
$ | 25,336 | |
Israel | |
| 1,683 | | |
| 6,318 | | |
| 8,001 | |
Canada | |
| 2,559 | | |
| | | |
| 2,559 | |
Europe | |
| 2,384 | | |
| - | | |
| 2,384 | |
Latin America | |
| 5,269 | | |
| - | | |
| 5,269 | |
Asia | |
| 1,182 | | |
| - | | |
| 1,182 | |
Others | |
| 23 | | |
| - | | |
| 23 | |
| |
$ | 38,436 | | |
$ | 6,318 | | |
$ | 44,754 | |
| |
Three months period ended June 30, 2024 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Unaudited | |
Geographical markets | |
| | |
| | |
| |
U.S.A | |
$ | 29,320 | | |
$ | - | | |
$ | 29,320 | |
Israel | |
| 1,725 | | |
| 3,326 | | |
| 5,051 | |
Canada | |
| 2,484 | | |
| | | |
| 2,484 | |
Europe | |
| 1432 | | |
| - | | |
| 1,432 | |
Latin America | |
| 4,119 | | |
| - | | |
| 4,119 | |
Asia | |
| 66 | | |
| - | | |
| 66 | |
Others | |
| | | |
| - | | |
| | |
| |
$ | 39,146 | | |
$ | 3,326 | | |
$ | 42,472 | |
| |
Year ended December 31, 2024 | |
| |
Proprietary Products | | |
Distribution | | |
Total | |
| |
U.S Dollars in thousands | |
| |
Audited | |
Geographical markets | |
| | |
| | |
| |
U.S.A | |
$ | 100,504 | | |
$ | - | | |
$ | 100,504 | |
Israel | |
| 5,506 | | |
| 19,506 | | |
| 25,012 | |
Canada | |
| 18,606 | | |
| - | | |
| 18,606 | |
Europe | |
| 9,457 | | |
| - | | |
| 9,457 | |
Latin America | |
| 4,936 | | |
| - | | |
| 4,936 | |
Asia | |
| 2,376 | | |
| - | | |
| 2,376 | |
Others | |
| 62 | | |
| - | | |
| 62 | |
| |
$ | 141,447 | | |
$ | 19,506 | | |
$ | 160,953 | |
|